

Supplementary1. All primers used in this study were listed below.

Primers	Sequences	Size
<i>optrA</i> -F1	CAGGTGGTCAGCGAACTAAGA	792bp
<i>optrA</i> -R1	AGCCAAGAGCAGTTCTGACC	
<i>optrA</i> -F	TTGTCCAAAGCCACCTTTG	1968bp
<i>optrA</i> -R	TTACATAACTTCCAATTCTCTC	
23S-V/F	AGTTTGACTGGGGCGGTC	429bp
23S-V/R	CCGGTCCTCTCGTACTA	
<i>rplC</i> -F	ATGACCAAAGGAATCTTAGGG	618bp
<i>rplC</i> -R	CACAGCTGATTTGATWGTGATT	
<i>rplD</i> -F	GCCGAATGTAGCATTATTCAA	617bp
<i>rplD</i> -R	CAAGCACCTCCTCAATTTGAGT	
<i>cfr</i> -F	TGAAGTATAAAGCAGGTTGGGAGTCA	746bp
<i>cfr</i> -R	ACCATATAATTGACCACAAGCAGC	
<i>cfr</i> (B)-F	TGAGCATATACGAGTAACCTCAAGA	293bp
<i>cfr</i> (B)-R	CGCAAGCAGCGTCTATATCA	
<i>cfr</i> (C)-F	CGACGCATCACCATTTCGAC	367bp
<i>cfr</i> (C)-R	GGCTTGAGGGCACCATAGTT	
<i>cfr</i> (D)-F	TGCGCTACTGGAAAAATTGGC	671bp
<i>cfr</i> (D)-R	TATAATTGGCCACAGGCAGCA	
<i>rplV</i> -F(efm)	GGACATGCTGCTGACGATA	486bp
<i>rplV</i> -R(efm)	ACCATTTAGCATCCCAGTCG	
<i>rplV</i> -F(efa)	GCCACGTTGCTGACGATAA	476bp
<i>rplV</i> -R(efa)	ACCCACTGATTGTCCCTCCT	
<i>poxA</i> -F	GGAAGTTGCTCAGTACGGCT	975bp
<i>poxA</i> -R	TCAATGCAGAGCAGGAAGCA	


Supplementary 2. Except *optrA* gene, the remaining genes such as *cfr*, *cfr(B)*, *cfr(C)*, *cfr(D)*, *rplD*, *rplC*, *rplV*, *poxtA* and 23S rRNA V region, concerned with linezolid resistance were amplified and sequenced in 20 *optrA*-positive *enterococcus faecalis* and *enterococcus faecium*.

Detections and mutations of these genes were presented below.

Isolates	Species	23S rRNA V region	<i>cfr</i>	<i>cfr(B)</i>	<i>cfr(C)</i>	<i>cfr(D)</i>	<i>rplC</i>	<i>rplD</i>	<i>rplV</i>	<i>poxtA</i>
8	efa	N	N	N	N	N	NM	W	NM	N
37	efa	N	N	N	N	N	NM	F101L	NM	N
91	efa	N	N	N	N	N	G4R	K8N, F101L, E202K	NM	N
154	efm	N	N	N	N	N	NM	K8Ter, F101L	NM	N
155	efa	N	N	N	N	N	NM	V4G, F101L, E202G	NM	N
185	efa	N	N	N	N	N	NM	F101L	NM	N
216	efa	N	N	N	N	N	G4D	F101L, E202G	NM	N
223	efa	N	N	N	N	N	G4K	F101L, E202G, V203W	NM	N
280	efa	N	N	N	N	N	NM	F101L, E202R	NM	N
297	efa	N	N	N	N	N	G4K	F101L	NM	N
366	efa	N	N	N	N	N	G4K	F101L, E201V	NM	N
397	efa	N	N	N	N	Y	G4R G7W	F101L, E202G	NM	N
402	efm	-	N	N	N	N	T150A	F101L	NM	NM
404	efa	N	N	N	N	N	NM	F101L, E202G	NM	N
413	efm	-	N	N	N	N	T150A	F101L, E202R	NM	N
421	efm	-	N	N	N	N	T150A	K8Ter, F101L	NM	N
422	efm	-	N	N	N	N	T150A	F101L	NM	N
446	efa	N	N	N	N	N	G4K	F101L	NM	N
550	efa	N	N	N	N	N	NM	F101L, V203G	NM	N
551	efa	N	N	N	N	N	NM	F101L, E202G	NM	N

Note: NM: No Mutations, N: No detections, Y: Positive detection. K: Lys, D: Asp, R: Arg, A: Ala, F: Phe, V: Val, E: Glu, W: Trp, L: Leu, T: Thr, N: Asn, Ter: Termination codon.

Supplementary3. The results of PFGE among 20 *optrA*-positive *enterococcus faecalis* and *enterococcus faecium*. We defined types according to the value of the homologous percentage. For example, if the percentage of isolates was over 80%, we considered them as the same type.



Supplementary4. This form revealed the results of the antimicrobial susceptibility test of *optrA*-positive strains in this study, including 18 antibiotics.

Number	Isolates	LZD	TDZ	PEN	AMP	IPM	TEC	VAN	KAN	NIT	RIF	FOS	ERY	CHL	TET	TIG	CIP	GEH500	STH1000
8	efa	8	1	1	<1	0.125	0.125	<0.5	256	16	2	64	>16	64	>8	0.125	8	N	P
37	efa	4	0.25	2	<1	0.25	0.125	1	>256	8	1	64	>16	32	>8	<0.125	>8	N	P
91	efa	2	0.25	2	<1	0.25	0.125	1	>256	8	1	64	>16	64	>8	0.25	>8	N	P
154	efm	1	<0.25	16	8	8	0.5	1	>256	8	4	64	>16	8	>8	<0.125	>8	N	P
155	efa	4	0.5	8	2	1	0.25	1	>256	8	2	64	>16	32	>8	0.125	>8	N	P
185	efa	4	0.5	2	<1	0.25	0.25	1	>256	16	1	64	>16	32	>8	0.25	>8	N	P
216	efa	2	0.5	4	<1	0.5	0.25	1	>256	16	2	128	>16	64	>8	0.125	>8	N	P
223	efa	1	<0.25	2	<1	0.25	0.25	1	32	8	1	128	>16	8	>8	0.125	>8	N	P
280	efa	1	<0.25	2	<1	0.5	0.25	<0.5	>256	<=4	2	64	>16	8	>8	0.125	>8	N	P
297	efa	4	0.5	2	<1	0.5	0.5	1	>256	<=4	2	128	>16	>64	>8	0.125	1	N	N
366	efa	4	0.5	2	<1	0.5	0.25	1	>256	<=4	16	64	>16	64	>8	<0.125	8	N	P
397	efa	2	0.5	2	<1	0.5	0.25	1	>256	8	2	64	>16	64	>8	0.125	8	N	P
402	efm	2	0.5	>32	>32	1	0.25	<0.5	>256	64	4	>128	>16	16	>8	<0.125	>8	N	P
404	efa	4	0.5	2	<1	0.5	0.5	<0.5	>256	<=4	2	>128	>16	64	>8	0.25	>8	P	P
413	efm	2	0.5	>32	>32	>8	0.5	1	>256	32	4	64	>16	16	>8	0.25	>8	N	P
421	efm	<0.5	<0.25	32	>32	>8	1	1	>256	16	2	64	>16	<=2	>8	4	8	N	P
422	efm	2	<0.25	>32	>32	>8	0.25	<0.5	>256	64	4	>128	>16	16	>8	<0.125	>8	N	P
446	efa	4	0.5	2	4	0.5	0.5	<0.5	>256	16	1	64	>16	>64	>8	<0.125	>8	N	P
550	efa	2	<0.25	16	<0.25	0.5	0.5	1	>256	16	1	64	>16	16	>8	0.25	>8	N	P
551	efa	8	1	2	<1	0.5	0.5	<0.5	>256	8	1	64	>16	>64	>8	0.25	>8	N	P

Note: LZD: Linezolid, TDZ: Tedizolid, PEN:Penicillin, AMP:Ampicillin, IPM:Imipenem, TEC:Teicoplanin, VAN:Vancomycin, KAN:Kanamycin, NIT:Nitrofurantoin, RIF:Rifampicin, FOS:Fosfomycin, ERY:Erythromycin, CHL:Chloramphenicol, TIG:Tigecycline, TET:Tetracycline, CIP:Ciprofloxacin, GEH500:Gentamicin 500ug/mL, STH1000:Streptomycin 1000u/mL, N:No Growth, P:Growth..